J&J Says CHMP Recommends Approval Of TALVEY Combo In Earlier Line Treatment Of R/R Multiple Myeloma
J&J EMEA announced the CHMP recommended approving TALVEY (talquetamab) in combination with daratumumab for treating adults with relapsed or refractory multiple myeloma who have had at least one prior therapy. The recommendation is based on Phase 3 results showing 81% progression-free survival and 89% overall survival at 24 months. If approved, it would be the only GPRC5D-targeting bispecific antibody combination therapy for second-line treatment.
How this was made
The 30-second read
Why it matters
The recommendation signals a high probability of approval, which could expand TALVEY's market and improve J&J's oncology pipeline outlook.
Market read
Regulatory progress for a major oncology drug can move J&J's stock and influence sector sentiment.
What to watch
Potential competition from other bispecifics and reimbursement negotiations could limit upside.
Background
The CHMP (Committee for Medicinal Products for Human Use) of the EMA issues a recommendation, a key step before formal European approval.
Ticker impact
CHMP recommends approval of TALVEY combo for relapsed/refractory multiple myeloma, a new regulatory step for J&J.
likely upward pressure as investors price in potential approval and expanded market opportunity
The recommendation is the first public disclosure of a favorable EMA decision for TALVEY, a high‑impact oncology asset.
Market effects
May boost biotech/oncology sector as EMA signals openness to bispecific antibodies.
European markets could see modest gains in pharma stocks.
Global investors will watch for FDA follow‑up, affecting worldwide J&J valuation.
Counterpoint
Approval is not guaranteed; EMA may still request more data, and market may have priced in the upside already.
Key entities
- companyJohnson & Johnson
Pharmaceutical giant developing TALVEY.
- regulatorEuropean Medicines Agency (EMA)
EU regulatory body issuing the recommendation.
